Picton Mahoney Asset Management’s BioMarin Pharmaceuticals BMRN Stock Holding History

Picton Mahoney Asset Management’s Portfolio BMRN Stock Details BMRN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2016 Q4	–	Sell	-18,800	Closed	-$1.74M	–	199
2016 Q3	$1.74M	Buy	+18,800	New	+$1.77M	0.12%	142
2015 Q4	–	Sell	-19,700	Closed	-$2.08M	–	308
2015 Q3	$2.08M	Buy	+19,700	New	+$2.63M	0.12%	130

Other funds holding BMRN

Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Sands Capital Management Arlington, Virginia $25.5B AUM 26.46% 1-Year Est. Return

Jennison Associates New York $167B AUM 44.17% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return

BBA

Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return

BIT

BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return

BFA

BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Picton Mahoney Asset Management's BMRN Position: Q4 2016 in Review

Picton Mahoney Asset Management sold out of BioMarin Pharmaceuticals (BMRN) in Q4 2016, closing a stake of 18,800 shares — an estimated $1.74M sold.

Picton Mahoney Asset Management first reported a position in BMRN in Q3 2015 and held it in 2 quarters. The position peaked at $2.08M in Q3 2015. 415 funds tracked by Wall St. Rank hold BMRN as of Q4 2016.

Picton Mahoney Asset Management reported no remaining BioMarin Pharmaceuticals position as of Q4 2016 after selling out during the quarter.
Picton Mahoney Asset Management sold 18,800 BioMarin Pharmaceuticals shares in Q4 2016, an estimated $1.74M.
Picton Mahoney Asset Management first reported a position in BioMarin Pharmaceuticals in Q3 2015 and held it in 2 quarters.
Picton Mahoney Asset Management's BioMarin Pharmaceuticals position peaked at $2.08M in Q3 2015.
415 funds tracked by Wall St. Rank held BioMarin Pharmaceuticals as of Q4 2016.

Based on Picton Mahoney Asset Management's 13F filing for Q4 2016, filed 15 Feb 2017.